Elevance Health Stock Plunges 29.6% in Q4: Buy, Hold or Sell?

Zacks12-21 04:00

U.S. health benefits company Elevance Health, Inc. ELV shares have declined 29.6% quarter to date, underperforming its industry and the S&P 500 Index. Closing at $366.48 on Thursday, near its 52-week ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2493447239?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/GmVc8.ZtfGjPFG_U83F8fA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e34d884fa2c79bf8b02903b1effd4c0b","is_english":true,"pubTime":"2024-12-21 04:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2493447239","market":"us","top_or_hot":-1,"title":"Elevance Health Stock Plunges 29.6% in Q4: Buy, Hold or Sell?","media":"Zacks","content":"<div>\n<p>U.S. health benefits company Elevance Health, Inc. ELV shares have declined 29.6% quarter to date, underperforming its industry and the S&P 500 Index. Closing at $366.48 on Thursday, near its 52-week ...</p>\n\n<a href=\"https://finance.yahoo.com/news/elevance-health-stock-plunges-29-200000272.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Elevance Health Stock Plunges 29.6% in Q4: Buy, Hold or Sell?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nElevance Health Stock Plunges 29.6% in Q4: Buy, Hold or Sell?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-21 04:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/elevance-health-stock-plunges-29-200000272.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>U.S. health benefits company Elevance Health, Inc. ELV shares have declined 29.6% quarter to date, underperforming its industry and the S&P 500 Index. Closing at $366.48 on Thursday, near its 52-week ...</p>\n\n<a href=\"https://finance.yahoo.com/news/elevance-health-stock-plunges-29-200000272.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0949170772.SGD","symbol_name":"Blackrock Global Equity Income A6 SGD-H","start_time":0,"source_url":"https://finance.yahoo.com/news/elevance-health-stock-plunges-29-200000272.html","article_id":"2493447239","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/GmVc8.ZtfGjPFG_U83F8fA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e34d884fa2c79bf8b02903b1effd4c0b"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2493447239","pubTimestamp":1734724800,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"U.S. health benefits company Elevance Health, Inc. ELV shares have declined 29.6% quarter to date, underperforming its industry and the S&P 500 Index. Closing at $366.48 on Thursday, near its 52-week low of $362.21, the company’s current share price seems an excellent opportunity to build a position in a renowned company. After all, you would much rather buy closer to the low than the high, right?Elevance Health, headquartered in Indianapolis, IN, has a market capitalization of $84.9 billion. Its peers, UnitedHealth Group Incorporated UNH and The Cigna Group CI, have also declined during the quarter-to-date period, but to a lesser extent than ELV.Elevance Health, Inc. price-eps-surprise | Elevance Health, Inc. Quote. Despite the headwinds, Elevance Health is well-positioned to grow in the long run backed by product expansions, revenue diversification, rate hikes and growth in commercial business. Premium rate increases and optimization of its government business by exiting poor-perform","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0949170772.SGD":"Blackrock Global Equity Income A6 SGD-H","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","LU1003077747.HKD":"BGF GLOBAL EQUITY INCOME \"A6\" (HKDHDG) INC","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","UNH":"联合健康","LU2552382058.USD":"WELLINGTON US BRAND POWER \"A\" (USD) ACC","LU1035773651.USD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (USD) INC","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0957791311.USD":"THREADNEEDLE (LUX) GLOBAL FOCUS \"ZU\" (USD) ACC","IE00B7KXQ091.USD":"Janus Henderson Balanced A Inc USD","LU0077335932.USD":"FIDELITY AMERICAN GROWTH \"A\" INC","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","IE00BFSS7M15.SGD":"Janus Henderson Balanced A Acc SGD-H","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","SG9999018865.SGD":"United Global Quality Growth Fd Cl Dist SGD-H","LU0187121727.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) INC","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","IE00BN29S564.USD":"JANUS HENDERSON BALANCED \"A3\" (USD) INC","LU0068578508.USD":"First Eagle Amundi International Cl AU-C USD","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","BK4139":"生物科技","SGXZ99366536.SGD":"United Global Innovation A Acc SGD-H","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0048584097.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) INC","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","SGXZ81514606.USD":"大华环球创新基金A Acc USD","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","IE00B775H168.HKD":"JANUS HENDERSON BALANCED \"A5M\" (HKD) INC","LU2237957902.USD":"NIKKO AM GLOBAL EQUITY \"F\" (USD) ACC","IE0005OL40V9.USD":"JANUS HENDERSON BALANCED \"A6M\" (USD) INC","LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","LU1934455863.HKD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","CI":"信诺保险","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","LU1489326972.SGD":"First Eagle Amundi International AHS-MD SGD-H","ELV":"Elevance Health","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC"},"translate_title":"Elevance Health股价第四季度暴跌29.6%：买入、持有还是卖出？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CI":1,"UNH":1,"ELV":1},"content_text":"U.S. health benefits company Elevance Health, Inc. ELV shares have declined 29.6% quarter to date, underperforming its industry and the S&P 500 Index. Closing at $366.48 on Thursday, near its 52-week low of $362.21, the company’s current share price seems an excellent opportunity to build a position in a renowned company. After all, you would much rather buy closer to the low than the high, right?\nElevance Health, headquartered in Indianapolis, IN, has a market capitalization of $84.9 billion. Its peers, UnitedHealth Group Incorporated UNH and The Cigna Group CI, have also declined during the quarter-to-date period, but to a lesser extent than ELV.\nELV Stock vs Industry, S&P 500, UNH & CI\n Image Source: Zacks Investment Research\nWeak Analyst Sentiment for ELV\nThe stock witnessed 10 downward estimate revisions for 2024 earnings in the past 60 days against no movement in the opposite direction. Again, for 2025 earnings, it witnessed 10 downward estimate revisions and only one upward movement during the same period. The Zacks Consensus Estimate for 2024 earnings of $33.20 per share declined 6.7% in the past 60 days. It beat earnings estimates thrice in the past four quarters and missed once, with the average surprise being negative 2.6%.\n\nElevance Health, Inc. Stock Price and EPS Surprise\n  \nElevance Health, Inc. price-eps-surprise | Elevance Health, Inc. Quote\n\nWhat’s Dragging Down ELV Stock?\nThere are multiple factors working here simultaneously. Medicaid membership has declined due to eligibility redeterminations and policy changes across states, leading to a loss of members and associated revenue. At the same time, rising medical costs, driven by seniors resuming elective procedures, are eroding profit margins. Adding to investor concerns, the company recently lowered its full-year 2024 earnings estimates, casting doubt on its future profitability.\nAnalysts have responded by lowering their target prices, reflecting concerns about the company’s performance potential in the current operating environment. Additionally, President-elect Donald Trump’s criticism of the pharmacy benefit management (PBM) industry, particularly its role in drug pricing, has added to the uncertainty. As a result, companies with significant PBM operations, including Elevance Health, UnitedHealth and Cigna, have seen share prices take a hit.\nWall Street Average Target Price for ELV Suggests an Upside\nBased on short-term price targets offered by 18 analysts, the Wall Street average price target is at $507.06 per share, suggesting a 38.44% upside from current levels.\n Image Source: Zacks Investment Research\nLong-Term Prospects to Drive ELV Stock\nDespite the headwinds, Elevance Health is well-positioned to grow in the long run backed by product expansions, revenue diversification, rate hikes and growth in commercial business. Premium rate increases and optimization of its government business by exiting poor-performing markets, poising it well for growth.\nThe company is reallocating resources to more profitable areas and making prudent acquisitions. ELV's ROIC of 10.61% is higher than the industry average of 8.47%, which indicates that the company is more efficient in generating returns from its invested capital than the industry.\nIts consistent dividend payouts and stock repurchases boost shareholders' value. Elevance Health’s dividend yield of 1.78% is higher than the industry average of 0.97%. ELV bought back shares worth $60 million in the third quarter. It had a leftover capacity of around $3.1 billion under its share buyback authorization as of Sept. 30, 2024. On Oct. 15, 2024, it authorized an increase of $8 billion to its share repurchase program.\nELV Stock: A Value-Driven Choice?\nElevance Health is trading at a discount compared to the industry average. It presents a compelling growth opportunity with its attractive forward 12-month price-to-earnings ratio of 10.39X, lower than its five-year median of 13.46X and the industry average of 13.26X. The company has a Value Score of A.\nTo Conclude\nWhile Elevance Health and the broader industry are facing weak analyst sentiment, the company’s long-term prospects remain strong. Itremains one of the best-positioned health insurance companies with a favorable valuation to achieve growth in commercial business.\nOverall, the outlook is largely neutral for ELV shares. It currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nUnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report\nCigna Group (CI) : Free Stock Analysis Report\nElevance Health, Inc. (ELV) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2493447239"}